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Abstract
Herbal medication use amongst people living with human immunodeficiency virus (PLWH) is widespread and understudied.
[AQ2] This study aimed to evaluate the prevalence of herbal medicine use amongst PLWH and possible contamination
with antiretrovirals (ARVs). Countrywide collection of herbal samples sold by street vendors in Nigeria for the following
indications: human immunodeficiency virus (HIV), acquired immune deficiency syndrome, fever and general weakness.
Samples were screened using a validated liquid chromatography-mass spectrometry/mass spectrometry method for the
presence of the following ARVs: efavirenz, nevirapine, lopinavir, darunavir, ritonavir, atazanavir, emtricitabine, tenofovir and
lamivudine. A survey was conducted among 742 PLWH attending four HIV clinics in Nigeria. Data were collected using a
structured questionnaire and analysed using IBM SPSS statistics version 22.0 (IBM Corp., 2013). [AQ3] Of the 138 herbal
medicine sampled, three (2%) contained detectable levels of tenofovir, emtricitabine and/or lamivudine. Additionally, of the
742 PLWH surveyed, 310 (41.8%) reported herbal medicine use. Among the users, 191 (61.6%) started taking herbals after
commencing HIV therapy while herbal medicine use preceded ARV treatment in 119 (38.4%) PLWH. We found herbal use
to be widespread among PLWH in Nigeria, with increasing use after commencing ARV. Three herbal preparations were
also found to contain detectable levels of ARV. This is a concern and should be studied widely across the region and
countries where herbal medicine use is prevalent and poorly regulated.
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Introduction
Prevalence of herbal medication use among people
living with human immunodeficiency virus (PLWH)
and contamination with medicinal products and certain
pharmaceutical agents has previously been reported,1
though understudied. Herbal contamination has not
been described for antiretrovirals (ARVs), despite sus-
picion and poor regulations of herbal practices in sub-
Saharan Africa (SSA).2,3
Globally, several studies have reported the use of
herbal medicines among PLWH either as part of com-
plimentary medicines or as a component for treating
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other ailments4 but few reports described the impact of
herbal medication use on patient safety, adherence and
health outcomes.5,6 Widespread use of herbals among
PLWH sabotages the intensified efforts to end human
immunodeficiency virus (HIV) epidemic by 2030.7 Use
of herbal medicines could be associated with toxicities,
reduced ARV adherence and poor health outcomes.5,6,8
In a Ugandan study, 63.5% of PLWH reported herbal
medicine use after HIV diagnosis and 32.8% use herbals
concomitantly with other pharmaceutical products
including ARV.9 Similarly, a Nigerian study reported
27.5% herbal use among PLWH prior to starting
ARV and 4.25% concomitant use with ARV.9,10
Nigeria and South Africa account for over 40% of
the HIV burden in SSA and over three million PLWH
in 2016 were living in Nigeria.11,12 Poor access to
healthcare, lack of qualified healthcare personnel,
healthcare cost, economic status, education and cultur-
al beliefs promote dissatisfaction with health services
and use of herbal medicines even while taking
ARV.13–15 Other challenges of healthcare in Nigeria
include: infrastructural, administrative and logistics
challenges. Marked variability in ARV access across
the country and complex peculiarities of the HIV pro-
grammes pose a significant challenge to PLWH and
promote utilisation of herbal medicines by patients.11
Although conflicting information have previously
been reported by some studies on the relationship
between concomitant use of herbal medicines and ARV
adherence,10,14,16 herbal use in HIV treatment should be
discouraged because of unknown constituents of the
herbal and potential drug interactions with ARVs.17
Use of herbals in relation to timing of ARV initia-
tion or safety is not well characterized.9,18 Users and
practitioners erroneously consider herbal medicines to
be safe without any safety prior evaluation.19,20
Furthermore, practitioners often have little or no
understanding of the modern approaches to evaluate
the safety of medicinal products.19,21
We sought to evaluate the prevalence of herbal med-
icine use by PLWH attending one rural and three
urban HIV clinics in Nigeria, and related this to the
time of ARV initiation. In addition, samples of tradi-
tional herbal medicines were collected from street ven-
dors across Nigeria and were screened for the presence
of ARVs using liquid chromatography-mass spectrom-
etry (LC-MS).
Methods
Contamination of herbal medications with ARVs
Herbal medicines were collected across eight states in
Nigeria between December 2014 and June 2015. The
protocol for sample collection was as follows: (i) street
vendors from both urban and rural settings were
approached by study investigators or assigned person-
nel, (ii) herbal medicines were requested for the follow-
ing indications: HIV, acquired immune deficiency
syndrome, fevers or non-specific symptoms (e.g. weak-
ness) known to be associated with HIV, (iii) herbal
vendors were not informed that samples were to be
used for research purposes to avoid any attempt by
the vendors to modify the preparation, (iv) only herbals
sold as powders or liquids were purchased, (v) instruc-
tions for use were recorded, as was the date and site.
A semi-quantitative screen for ARV contamination of
herbal medicines was performed at the University of
Liverpool by LC-MS for the following ARVs: efavirenz,
nevirapine, lopinavir, darunavir, ritonavir, atazanavir,
emtricitabine, tenofovir and lamivudine, using a method
adapted from Else et al.22 This method enabled the simul-
taneous measurement of nine ARVs and was modified
based on the suspected solubility of the different ARVs.
Sample pre-treatment. Herbal powders were weighed and
dissolved in both water and dimethyl sulfoxide in order
to optimise recovery due to different solubility of pos-
sible contaminants, at a stock concentration of 10 mg/
mL. Working solutions were prepared by further dilut-
ing the stock (1:1) with mobile phase. Control (drug-
free) mobile phase and blank herbal extracts (herbal
controls) were prepared to check the background
response of the LC-MS assay. Reference standards
spiked with nine ARVs (efavirenz, nevirapine, lopina-
vir, darunavir, ritonavir, atazanavir, emtricitabine,
tenofovir and lamivudine) at two concentrations (50
ng/mL and 100 ng/mL) were prepared.
Semi-quantitative LC-MS/MS. Blanks, reference standards
and unknown samples (sourced herbal extracts) were
injected (10 mL) onto the LC column coupled to a triple
quadrupole mass spectrometer (TSQ Ultra; Thermo
Scientific, Hemel Hempstead, UK). Data acquisition
and processing was performed using LC QuanTM soft-
ware (Thermo Scientific, Hemel Hempstead, UK).
Herbal contamination was determined by semi-
quantitative LC-MS assay (no internal standard or cal-
ibrators were used). An estimate of the amount of drug
within contaminated samples was derived by compar-
ing chromatographic peak areas of the samples against
peak areas of known concentrations of tenofovir, emti-
citabine and lamivudine spiked in water after correct-
ing for background signal from a known negative
herbal sample. Two rounds of analysis (initial screening
using 10 mg/mL and confirmatory tests using 50 mg/
mL) were performed before accepting the presence of
ARV contamination in the sample. Detectable drug
was confirmed if the response (chromatographic peak
area; arbitrary units) of the unknown sample was at
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least five times greater than the response of the blank
herbal extract (assay background). A semi-quantitative
value per milligram of herbal powder was calculated
based on the response of the reference standards
minus the assay background interference. For samples
that showed presence of drug during screening, addi-
tional confirmatory experiments were performed using
higher (50 mg/mL) concentrations of herbal extract.
Survey of herbal medication use among PLWH
A clinical survey of PLWH attending ARV facilities in
one rural (Rural Hospital, Idong) and three urban HIV
facilities (Specialist Hospital, Gombe, Faith Alive
Foundation Clinic, Jos, and Dalhatu Araf Specialist
Hospital, Lafia) was conducted. Using a non-
probability sampling technique, 500 PLWH were sur-
veyed from Faith Alive Foundation Clinic, 199 from
Dalhatu Araf Specialist Hospital, 33 from Specialist
Hospital Gombe and 10 from Rural Hospital, Idong,
respectively. The national prevalence rate of HIV in
Nigeria is 3.2%; Kaduna, Gombe, Plateau and
Nassarawa states have HIV prevalence rate of 9.2%,
8.1%, 3.4% and 2.3%, respectively. These surveyed clin-
ics attend to over 6000 PLWH and the Faith Alive
Foundation Clinic in Jos attends to over 5000 PLWH
per month, while Rural Hospital, Idong, a primary
healthcare setting, attends to less than 50 PLWH.23,24
Inclusion criteria were: known HIV-antibody posi-
tive patients attending clinic, any age, willing to partic-
ipate in the survey. For children less than 18 years old,
parents were asked for consent and if willing, provided
responses to the survey. Hospitalised patients, patients
who were acutely unwell and any unconfirmed patient
in the clinic were excluded. We utilised a structured
questionnaire adapted from Langlois-Klassen et al.
who previously evaluated herbal medication use
among PLWH.9 The questionnaire was modified for
our purpose and was applied to evaluate use of
herbal medications across age, gender, education,
employment status, date of diagnosis, date of starting
herbal medications, type of herbal medication, source
of recommendation for herbal use, source of procure-
ment of herbal, reasons for use and perceived effective-
ness of the herbals. Someone was considered a herbal
user if he/she utilises concoctions (from known or
unknown plant products) from herbal vendors or
plant product recommended by family, friend or any-
body. The primary outcome was prevalence of herbal
medication use among PLWH. Secondary outcomes
were use of herbals in relation to initiation of antire-
troviral drugs, differences by gender, by age, by educa-
tional attainment, employment status and perception
of benefit from herbal use. Herbal sample collection
from vendors was random, and collection at different
regions of the country was ensured for fair representa-
tion of different regions of the country.
Statistical analysis. Data were analysed using IBM SPSS
statistics version 22.0 (IBM Corp., 2013). Participants
who answered positively when asked, ‘Do you use
herbal medicine?’ were considered as herbal medicine
users. Data on herbal use and baseline social and
demographic factors were pooled across all four centres
to produce aggregate, descriptive overall frequencies at
5% level of significance (Table 1). We then compared
social and demographic factors in PLWH who used or
did not use herbal medicines. First, univariate analysis
was performed using binary logistic regression with
herbal use as the dependent variable. Next, all univar-
iate associations with P0.1 were included in the final
multivariable model. Groups were compared for rela-
tionships and confounders on the dependent variable
(use of herbal medication) were resolved using multiple
regression models (Table 2).
Ethical approval. Ethics approval for the survey was
obtained from Dalhatu Araf Specialist Hospital,
Lafia, Faith Alive Foundation Hospital and PMTCT
Centre, Jos (protocol assigned number: FAFHREC/
08/34/5) and parental consent for including children
was sought from parents before interviewing the
parents for their children’s information. Only verbal
consent and permission from hospital management
was obtained from patient in primary healthcare
Idong and Gombe Specialist Hospital.
Results
A total of 742 (approximately 12% of patients receiv-
ing treatments in these facilities) consecutively attend-
ing PLWH aged between 2 and 91 years were surveyed
across the four centres. Of these, 715 (96.4%) were
adults aged 18 and above, 457 (61.6%) were female,
281 (37.9%) were males, and details of gender were
missing in 4 (0.9%). Further details of demographic
characteristics are provided in Table 1. Of the 742
PLWH surveyed, 594 (80.1%) were receiving ARVs.
Herbal use was reported in a total of 310 individuals
(41.8%). Of these, 119 (38.4%) took herbals prior to
starting ARV while 191 (61.6%) started taking herbals
after starting ARV (Table 2). Educational attainment
was significantly associated with herbal medication use;
individuals with secondary and tertiary education were
more likely (70%) than those with little or no education
(26.1%) to use herbals (P< 0.001) and with employ-
ment status (70.7% of the employed vs. 28.4% of
unemployed patients admitted using herbals,
P< 0.001). Time from diagnosis of HIV (P¼ 0.73)
and whether individuals were receiving ARVs
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(P¼ 0.53) were not significantly associated with herbal
medication use. PLWH who use herbals did so for a
variety of reasons: to cure HIV (46.8%), or following
the advice of family (67.4%) or friends (31.6%).
Altogether, 40.3% said they felt herbals were ineffec-
tive for HIV while 4.5% believed themselves cured
(Table 2). Ingestion of herbal medications while on
ARVs was more likely in the elderly (OR 2.31; 95%
CI 1.34, 3.99) and the employed (OR 1.23; CI 0.89,
1.70) compared to the unemployed (Table 3).
As an extension to this study, 138 herbal samples
were sourced from herbal vendors in diverse locations
across Nigeria to assay for the presence of ARVs. Of
the 138 samples collected and analysed, three (2%)
contained detectable ARVs. One sample from Jos con-
tained tenofovir and emtricitabine (estimated as 0.02
ng/mg powder and 0.01 ng/mg powder, respectively),
while two samples from Ibadan contained tenofovir
(estimated as <0.01 and 0.13 ng/mg powder) and emtri-
citabine (estimated as <0.01 ng/mg powder), with one
of these also containing lamivudine (estimated as 0.02
ng/mg powder). Other ARV classes were not detected.
Dosing recommendations provided by the herbal
vendors are often not precise. We found a typical dose
recommendation was ‘3 fingers’ or scoops of medicinal
powder in the palm of the hand, conservatively estimat-
ed as 1–2 teaspoons (1 teaspoon estimated as 5 g). Based
on these recommendations, a single dose of 2 teaspoons
(approximately 10 g) of contaminated herbal powder
could potentially deliver up to 1.3 mg of tenofovir, 0.1
mg of emtricitabine and 0.2 mg of lamivudine. Although
amount of drug detected is small, repeated exposure, or
exposure to higher doses with different batches or prep-
arations, could promote drug resistance.
In Nigeria, tenofovir and emtricitabine are available
in fixed-dose combination as TRUVADAVR . We wanted
to examine if the discrepancy in the amount of tenofovir
and emtricitabine observed could have been explained
by differential degradation when crushed or dissolved,
or recovery during the extraction process. Recovery
from dissolved TRUVADAVR tablets in water at room
temperature carried out after 12 weeks and 9 months,
respectively, was 63.2% and 1.47% for emtricitabine,
compared with 0.8% and 1.47% for tenofovir. There
were also considerable differences in drug solubility,
recovery (extraction efficiency) and matrix effects (ion
suppression) between different herbal preparations,
which more likely explained the differences in measured
quantity between both drugs.
Discussion
We observed widespread use of herbal medicines in
Nigeria (Table 1) regardless of age, gender, educational
Table 1. Prevalence of social and demographic factors in PLWH who use or do not use herbal medicines.
Variable
Use herbal medications
(n¼ 310) n (%)
Do not use herbal medications
(n¼ 432) n (%)
Age (years)
• Median (range) 33 (2–91) 32 (13–74)
Gender
• Male
• Female
• Missing data
119 (38.4)
191 (61.6)
162 (37.9)
266 (62.1)
4 (0.9)
Level of education
• Little or no education
• Secondary and tertiary education
• Missing data
81 (26.1)
217 (70.0)
12 (3.9)
139 (32.1)
285 (66.0)
8 (1.9)
Employment status
• Employed
• Unemployed
• Missing data
219 (70.7)
88 (28.4)
3 (0.9)
281 (65.1)
140 (32.4)
11 (2.5)
Months since HIV diagnosis
• <6 months
• >6 months
• Missing data
146 (47.1)
152 (49.0)
12 (3.9)
136 (31.5)
284 (65.7)
12 (2.8)
Commenced ARVs
• Yes
• No
• Missing data
259 (83.6)
45 (14.5)
6 (1.9)
335 (77.5)
78 (18.1)
19 (4.4)
HIV: human immunodeficiency virus; ARV: antiretroviral.
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or employment status. Our data are consistent with
previous studies conducted in this region.9,25 A total
of 594 (80%) of PLWH were receiving ARV and
herbal medicine use was highly prevalent in patients
receiving HIV treatment (259/594 [43.6%] of those
receiving ARV use herbal or traditional medicines).
Among the herbal users, 38.4% were using these rem-
edies prior to initiation of ARVs, while 61.2% started
using it after HIV diagnosis (Tables 1 and 2).
Of concern, 45 (14.5%) of herbal users were yet to
initiate ARVs which could be detrimental to their treat-
ment in the future if exposed to low levels of ARV in
herbal remedies (Table 1). Previous reports of low-level
ARV exposure to neonate during PMTCT suggest that
continuous low-level exposure to ARVs could drive
resistance.25,26 Our finding of contamination of herbals
with ARVs is a concern, though concentration was
very small and may not be sufficient to drive resistance,
finding contamination in herbals is detrimental to
treatment and HIV programme success. Around half
of the subjects perceived use of herbal medicines to
either moderately or completely relieve symptoms
such as headaches, fever and generalised
body weakness.
We found 2% of herbal medicines contained small,
but detectable quantities of ARVs, yielding an estimat-
ed dose of 0.1–1.3 mg ingested per dosing occasion. The
clinical relevance of this is unclear. However, continu-
ous low-level exposure to drug can lead to resistance,
provided sufficient drug is present to drive selection
pressure for resistant mutants. Furthermore, potential
drug–drug interaction of herbals and ARVs as well as
safety8,17 was difficult to ascertain since constituents of
the herbal medicines were unknown.27 Although the
concentrations detected were very low, actual concen-
trations may have been higher given the different effi-
ciencies of extraction and degradation over time that
were observed.
The finding that traditional or herbal remedies may
contain pharmaceutic agents is not new. Previously,
herbal medicines have been found to contain antipyret-
ics, anti-inflammatory agents or steroids, diuretics,
antidiabetics, sedatives, antihistamines and vasodila-
tors through accidental or deliberate contamination.28
Accidental contamination may result from carryover of
drug during local manufacture of medicines; however,
this is less likely here as HIV drugs are not locally co-
manufactured with herbals to our knowledge. It is dif-
ficult to ascertain whether contamination was
Table 3. Association of surveyed variables and herbal medication use among PLWH.
Univariate analysis Multivariate analysis
Variable b
Odds ratio (OR) (95%
confidence interval) P b
Odds ratio (OR)
(95% confidence interval) P
Age 0.688 1.990 (1.183, 3.347) 0.009 0.839 2.314 (1.343,3.987) 0.003
Gender –0.039 0.797 (0.712, 1.298) 0.797
Level of education 0.248 1.282 (0.930, 1.766) 0.130 0.190 1.209 (0.868, 1.686) 0.262
Employment status 0.192 1.228 (0.887, 1.696) 0.228
Months since HIV diagnosis –0.688 0.502 (0.370, 0.681) <0.001 –0.724 0.485 (0.355, 0.663) <0.001
Commenced ARVs 0.154 1.167 (0.080, 1.696) 0.418
HIV: human immunodeficiency virus; ARV: antiretroviral.
Table 2. Source of recommendations, reasons for use, when
herbal was started and perceived effectiveness among PLWH
who use herbal medication (n¼ 310).
Variable
Use herbal
medications
(n¼ 310) n (%)
When did you start using herbal medications?
• Pre-HIV diagnosis
• Post-HIV diagnosis
119 (38.4)
191 (61.6)
Who recommended the herbal medications
• Family
• Friends
• Missing data
209 (67.4)
98 (31.6)
3 (1.0)
Source of herbal medicines
• City vendors
• Village herbalist
• Others
• Missing data
108 (34.8)
145 (46.8)
15 (4.8)
42 (13.6)
Reasons for herbal medication use
• To Relieve Symptoms
• To achieve cure of disease
• Others
• Missing data
108 (34.8)
145 (46.8)
15 (4.8)
42 (13.6)
Perceived effectiveness of herbal medication
• No help
• Moderate relieve of symptoms
• Completely relieved symptoms
• Cures disease (HIV) completely
• Missing data
125 (40.3)
89 (28.7)
43 (13.9)
14 (4.5)
39 (12.6)
HIV: human immunodeficiency virus.
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deliberate or accidental in this case. HIV drugs are dis-
pensed free of charge through the National Treatment
Programme; their use and belief that they are beneficial
for the treatment of HIV disease may provide both the
opportunity and the motive for any deliberate contam-
ination. Herbalists and their medicines can play an
important role in supplementing and supporting HIV
treatment in treatment settings18,29 where weak health
systems and complex cultural beliefs around symptom
management30 promote widespread herbal use.
Enforcing the regulation of herbal medicine practices3
and re-evaluating policies guiding herbal practitioners
in Nigeria is urgently required to avoid harmful prac-
tices that put the general public at risk.
Limitations
We were not able to ascertain how herbal use influ-
enced engagement with HIV services, or adherence to
ARVs although these are important questions to
address in future research. Moreover, we were only
able to assess PLWH already engaged with treatment
services. There is currently no clear understanding of
positive or negative effects of traditional medicines as
adjunctive treatment in PLWH. However, the lack of
regulation and standardisation in these preparations
argues strongly for further work to confirm our find-
ings in other countries where herbal medicine use is
prevalent and to understand whether ARV contamina-
tion of herbal medicines has a negative impact on ARV
programmes through the generation of drug resistance.
Surveys were only conducted in small population from
northern Nigeria, which may vary from other regions
of the country. Therefore, a larger study that aims at
ensuring fair representation of all the regions of
Nigeria is required.
Conclusion
Herbal medicine use was widespread and mostly uti-
lised concomitantly with ARVs. Although a fairly large
proportion utilised herbals prior to ARV initiation, co-
administration of herbal medicines with ARVs is con-
cerning, since the constituents and safety profiles of the
herbal medicines are unknown. Toxicity and herbal–
ARV interactions are uncharacterised which favours
urgent evaluation of policies by authorities to regulate
their practices. Erroneous perception of herbals to
relieve HIV symptoms or cure disease is a problem
and herbals need to be further evaluated for their
medicinal benefits. Finally, further evaluation of our
findings by researchers to establish the best approach
to monitor and enforce safe practices of herbalist for
public safety of herbal products as well as collaborative
research of medicinal herbs is required.
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